X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1867) 1867
Publication (151) 151
Book Review (9) 9
Book / eBook (6) 6
Newsletter (5) 5
Newspaper Article (5) 5
Conference Proceeding (4) 4
Book Chapter (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1724) 1724
female (1606) 1606
index medicus (1125) 1125
endometrial cancer (989) 989
oncology (932) 932
cancer (868) 868
middle aged (791) 791
endometrial neoplasms - pathology (635) 635
aged (611) 611
adult (573) 573
immunohistochemistry (426) 426
carcinoma (399) 399
tumors (395) 395
pathology (390) 390
endometrium (362) 362
prognosis (355) 355
expression (344) 344
endometrial neoplasms - genetics (334) 334
endometrial neoplasms - metabolism (322) 322
research article (297) 297
medicine (295) 295
research (291) 291
aged, 80 and over (288) 288
endometrial carcinoma (288) 288
analysis (274) 274
endometrial neoplasms - immunology (264) 264
animals (258) 258
breast-cancer (254) 254
neoplasm staging (252) 252
risk factors (246) 246
science (244) 244
multidisciplinary sciences (233) 233
obstetrics & gynecology (232) 232
cell line, tumor (231) 231
gene expression (220) 220
health aspects (220) 220
mutation (209) 209
ovarian cancer (209) 209
cell biology (204) 204
genetic aspects (200) 200
male (194) 194
proteins (185) 185
adenocarcinoma (182) 182
metastasis (177) 177
breast cancer (170) 170
diagnosis (167) 167
survival (165) 165
immunology (159) 159
mice (157) 157
apoptosis (155) 155
gene expression regulation, neoplastic (153) 153
estrogen (152) 152
care and treatment (150) 150
risk (148) 148
cancers and neoplasms (144) 144
genes (144) 144
case-control studies (138) 138
development and progression (136) 136
endometrial neoplasms - diagnosis (135) 135
cancer research (134) 134
women (131) 131
adenocarcinoma - pathology (128) 128
oncology, experimental (125) 125
uterus (125) 125
cells (124) 124
medical prognosis (122) 122
studies (122) 122
biology (121) 121
retrospective studies (121) 121
biomarkers (118) 118
chemotherapy (118) 118
ovarian neoplasms - pathology (118) 118
gynecology (117) 117
colorectal-cancer (116) 116
genetics (116) 116
patients (116) 116
cell proliferation (114) 114
surgery (114) 114
microsatellite instability (113) 113
biomedicine (111) 111
carcinoma, endometrioid - pathology (107) 107
signal transduction (107) 107
biomarkers, tumor - metabolism (105) 105
obstetrics and gynecology (105) 105
kinases (99) 99
medical research (97) 97
endometrial neoplasms - drug therapy (96) 96
health risk assessment (96) 96
medicine and health sciences (96) 96
endometrial neoplasms - mortality (95) 95
ovarian-cancer (95) 95
colorectal cancer (94) 94
gynecological tumors (94) 94
article (93) 93
neoplasm invasiveness (91) 91
follow-up studies (90) 90
deoxyribonucleic acid--dna (89) 89
medicine & public health (88) 88
biomarkers, tumor - analysis (87) 87
tumor cells, cultured (87) 87
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1833) 1833
Russian (18) 18
Chinese (11) 11
Japanese (8) 8
Polish (5) 5
French (3) 3
German (2) 2
Romanian (2) 2
Bulgarian (1) 1
Danish (1) 1
Hungarian (1) 1
Italian (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 10/2012, Volume 7, Issue 10, p. e47045
High macrophage infiltration has been correlated to improved survival in colorectal cancer (CRC). Tumor associated macrophages (TAMs) play complex roles in... 
CELL LUNG-CANCER | ISLAND METHYLATOR PHENOTYPE | COLON-CANCER | HUMAN PROSTATE-CANCER | MICROSATELLITE INSTABILITY | MULTIDISCIPLINARY SCIENCES | REGULATORY T-CELLS | TUMOR-ASSOCIATED MACROPHAGES | INFILTRATING MACROPHAGES | PATIENT SURVIVAL | ENDOMETRIAL CANCER | Immunohistochemistry | Antigens, CD - immunology | Microsatellite Instability | Prognosis | Rectum - pathology | Colorectal Neoplasms - genetics | Humans | Receptors, Cell Surface - analysis | Colon - immunology | Colorectal Neoplasms - diagnosis | Antigens, CD - analysis | Nitric Oxide Synthase Type II - analysis | DNA Methylation | Nitric Oxide Synthase Type II - immunology | Antigens, Differentiation, Myelomonocytic - immunology | Macrophages - immunology | Macrophages - pathology | Colon - pathology | Rectum - metabolism | Rectum - immunology | Receptors, Cell Surface - immunology | Colon - metabolism | Macrophages - metabolism | Phenotype | Colorectal Neoplasms - immunology | Antigens, Differentiation, Myelomonocytic - analysis | CpG Islands | Colorectal Neoplasms - pathology | Genetic aspects | Research | Macrophages | Analysis | Colorectal cancer | Correlation | Colorectal carcinoma | Microsatellite instability | Cancer therapies | Subgroups | Metastases | Ethics | Genotype & phenotype | Angiogenesis | Surgery | Tumorigenesis | Growth factors | CpG islands | Cell survival | Microsatellites | Stability | Invasiveness | Patients | Survival | Nitric-oxide synthase | Studies | CD163 antigen | Pathology | Screening | Nitric oxide | Medical prognosis | Infiltration | Health risk assessment | Tumors | Cancer | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4473 - 4481
Purpose: Recent studies show that colorectal tumors with high microsatellite instability (MSI-H) have increased immunogenicity and response to immunotherapy... 
ISLAND METHYLATOR PHENOTYPE | TUMOR-INFILTRATING LYMPHOCYTES | INSTABILITY | ONCOLOGY | COLORECTAL-CANCER | LYNCH SYNDROME | MUTATIONS | EXPRESSION | Microsatellite Instability | CD8-Positive T-Lymphocytes - pathology | Colorectal Neoplasms - genetics | Colorectal Neoplasms, Hereditary Nonpolyposis - genetics | Colorectal Neoplasms, Hereditary Nonpolyposis - pathology | Humans | Middle Aged | Colorectal Neoplasms, Hereditary Nonpolyposis - immunology | Endometrial Neoplasms - diagnosis | Colorectal Neoplasms - diagnosis | Microsatellite Repeats - genetics | Tumor Microenvironment - immunology | Endometrial Neoplasms - immunology | Colorectal Neoplasms - immunology | Tumor Microenvironment - genetics | Endometrial Neoplasms - genetics | Colorectal Neoplasms, Hereditary Nonpolyposis - diagnosis | Immunotherapy | Endometrial Neoplasms - pathology | Female | Aged | CD8-Positive T-Lymphocytes - immunology | Colorectal Neoplasms - pathology | Multiplexing | Populations | Endometrial cancer | CD8 antigen | Clinical trials | Fluorescence | Microsatellite instability | Macrophages | Metastases | Granzyme B | Compartments | Endometrium | Immune system | Medical research | Immune response | Microsatellites | Stability | Stroma | Immunogenicity | Lymphocytes B | Experimental design | PD-L1 protein | Infiltration | Hormone replacement therapy | Health risk assessment | Tumors | Cancer | microsatellite instability | immune microenvironment | Uterine cancer | hereditary cancers | Lynch syndrome
Journal Article
Anticancer Research, ISSN 0250-7005, 08/2009, Volume 29, Issue 8, pp. 2875 - 2884
Background: To identify immunosuppressive elements present in ovarian cancer associated ascites. Patients and Methods: Ascites and plasma were obtained from... 
Cell mediated immunity | Cytokines | Ascites | Chemokines | Ovarian cancer | DENDRITIC CELLS | PANCREATIC-CANCER | PERIPHERAL-BLOOD | chemokines | CYTOTOXIC T-LYMPHOCYTES | TUMOR-INFILTRATING LYMPHOCYTES | ascites | ADOPTIVE TRANSFER | ONCOLOGY | IN-VIVO | cytokines | cell mediated immunity | ANTIGEN-PRESENTING CELLS | PROGNOSTIC-SIGNIFICANCE | ENDOTHELIAL GROWTH-FACTOR | CD8-Positive T-Lymphocytes - pathology | Prognosis | Humans | Middle Aged | Cystadenocarcinoma, Serous - metabolism | Endometrial Neoplasms - metabolism | Ovarian Neoplasms - pathology | CD4-Positive T-Lymphocytes - pathology | Adenocarcinoma, Clear Cell - immunology | T-Lymphocytes, Regulatory - immunology | CD4-Positive T-Lymphocytes - immunology | Antigen-Presenting Cells - pathology | Endometrial Neoplasms - immunology | Flow Cytometry | Fallopian Tube Neoplasms - immunology | Aged, 80 and over | Ascites - immunology | CD8-Positive T-Lymphocytes - metabolism | Adult | Female | Ovarian Neoplasms - metabolism | Cystadenocarcinoma, Serous - immunology | Peritoneal Neoplasms - immunology | Peritoneal Neoplasms - pathology | Cystadenocarcinoma, Serous - secondary | Antigen-Presenting Cells - metabolism | Cytokines - metabolism | Adenocarcinoma, Clear Cell - metabolism | CD4-Positive T-Lymphocytes - metabolism | Fallopian Tube Neoplasms - pathology | Survival Rate | Chromium - metabolism | Antigen-Presenting Cells - immunology | Endometrial Neoplasms - secondary | Adenocarcinoma, Clear Cell - secondary | Ascites - metabolism | Peritoneal Neoplasms - metabolism | Aged | Fallopian Tube Neoplasms - metabolism | CD8-Positive T-Lymphocytes - immunology | Ascites - pathology | Ovarian Neoplasms - immunology
Journal Article
by Hendry, Shona and Salgado, Roberto and Gevaert, Thomas and Russell, Prudence A and John, Tom and Thapa, Bibhusal and Christie, Michael and van de Vijver, Koen and Estrada, M V and Gonzalez-Ericsson, Paula I and Sanders, Melinda and Solomon, Benjamin and Solinas, Cinzia and Van den Eynden, Gert G G M and Allory, Yves and Preusser, Matthias and Hainfellner, Johannes and Pruneri, Giancarlo and Vingiani, Andrea and Demaria, Sandra and Symmans, Fraser and Nuciforo, Paolo and Comerma, Laura and Thompson, E A and Lakhani, Sunil and Kim, Seong-Rim and Schnitt, Stuart and Colpaert, Cecile and Sotiriou, Christos and Scherer, Stefan J and Ignatiadis, Michail and Badve, Sunil and Pierce, Robert H and Viale, Giuseppe and Sirtaine, Nicolas and Penault-Llorca, Frederique and Sugie, Tomohagu and Fineberg, Susan and Paik, Soonmyung and Srinivasan, Ashok and Richardson, Andrea and Wang, Yihong and Chmielik, Ewa and Brock, Jane and Johnson, Douglas B and Balko, Justin and Wienert, Stephan and Bossuyt, Veerle and Michiels, Stefan and Ternes, Nils and Burchardi, Nicole and Luen, Stephen J and Savas, Peter and Klauschen, Frederick and Watson, Peter H and Nelson, Brad H and Criscitiello, Carmen and O'Toole, Sandra and Larsimont, Denis and de Wind, Roland and Curigliano, Giuseppe and André, Fabrice and Lacroix-Triki, Magali and van de Vijver, Mark and Rojo, Federico and Floris, Giuseppe and Bedri, Shahinaz and Sparano, Joseph and Rimm, David and Nielsen, Torsten and Kos, Zuzana and Hewitt, Stephen and Singh, Baljit and Farshid, Gelareh and Loibl, Sibylle and Allison, Kimberly H and Tung, Nadine and Adams, Sylvia and Willard-Gallo, Karen and Horlings, Hugo M and Gandhi, Leena and Moreira, Andre and Hirsch, Fred and Dieci, Maria V and Urbanowicz, Maria and Brcic, Iva and Korski, Konstanty and Gaire, Fabien and Koeppen, Hartmut and Lo, Amy and Giltnane, Jennifer and Rebelatto, Marlon C and Steele, Keith E and Zha, Jiping and Emancipator, Kenneth and Juco, Jonathan W and Denkert, Carsten and Reis-Filho, Jorge and Loi, Sherene and Fox, Stephen B
Advances in anatomic pathology, ISSN 1072-4109, 11/2017, Volume 24, Issue 6, pp. 311 - 335
Journal Article
Cancer Letters, ISSN 0304-3835, 2015, Volume 359, Issue 2, pp. 307 - 313
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 09/2017, Volume 59, pp. 109 - 116
Journal Article
Cancer, ISSN 0008-543X, 09/2008, Volume 113, Issue 6, pp. 1387 - 1395
BACKGROUND. The purpose of this study was to investigate whether tumor‐infiltrating immune cells in biopsy specimens can be used to predict the clinical... 
mast cell | macrophage | CD8+ T cell | stage IV | nonsmall cell lung cancer | Nonsmall cell lung cancer | Mast cell | Stage IV | CD8 | T cell | Macrophage | ANGIOGENESIS | CD8(+) T cell | MAST-CELLS | ENDOMETRIAL CANCER | BREAST-CANCER | CYTO-TOXICITY | ONCOLOGY | TUMOR-ASSOCIATED MACROPHAGES | PROGNOSTIC-SIGNIFICANCE | CARCINOMA | PROGRESSION | LYMPHOCYTES | Lung Neoplasms - drug therapy | CD8-Positive T-Lymphocytes - pathology | Prognosis | Lung Neoplasms - mortality | Stromal Cells - pathology | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antigens, CD - metabolism | Lymphocyte Activation - immunology | Carcinoma, Squamous Cell - mortality | Adult | Female | Macrophages - immunology | Carcinoma, Non-Small-Cell Lung - pathology | Mast Cells - immunology | Macrophages - pathology | Adenocarcinoma - immunology | Stromal Cells - immunology | Survival Rate | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Carcinoma, Squamous Cell - immunology | Adenocarcinoma - secondary | Carcinoma, Non-Small-Cell Lung - immunology | Lung Neoplasms - immunology | Carcinoma, Squamous Cell - drug therapy | Lymphocytes, Tumor-Infiltrating - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antigens, Differentiation, Myelomonocytic - metabolism | Mast Cells - pathology | Carcinoma, Squamous Cell - secondary | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | CD8-Positive T-Lymphocytes - immunology | Neoplasm Staging | Adenocarcinoma - mortality | Lymphocytes, Tumor-Infiltrating - immunology | Patient outcomes | CD8 lymphocytes | Physiological aspects | Research | Macrophages | Lung cancer, Non-small cell | Biological markers
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2017, Volume 23, Issue 19, pp. 5836 - 5845
Purpose: Carcinosarcomas (CS) are highly aggressive gynecologic malignancies containing both carcinomatous and sarcomatous elements with heterogeneous HER2/neu... 
EPITHELIAL-MESENCHYMAL TRANSITION | TRASTUZUMAB PLUS DOCETAXEL | PHASE-II TRIAL | GYNECOLOGIC-ONCOLOGY-GROUP | ONCOLOGY | GASTRIC-CANCER | SEROUS CARCINOMA | METASTATIC BREAST-CANCER | ENDOMETRIAL CARCINOSARCOMA | PRECLINICAL PROFILE | MONOCLONAL-ANTIBODY | Receptor, ErbB-2 - genetics | Uterine Neoplasms - pathology | Humans | Ovarian Neoplasms - pathology | Antibody-Dependent Cell Cytotoxicity - immunology | Pyrrolidinones - immunology | Immunoconjugates - administration & dosage | Indoles - administration & dosage | Carcinosarcoma - immunology | Immunoconjugates - immunology | Ovarian Neoplasms - genetics | Pyrrolidinones - administration & dosage | Female | Receptor, ErbB-2 - antagonists & inhibitors | Receptor, ErbB-2 - immunology | Gene Expression Regulation, Neoplastic - drug effects | Ovarian Neoplasms - drug therapy | Carcinosarcoma - pathology | Uterine Neoplasms - genetics | Maytansine - analogs & derivatives | Indoles - immunology | Trastuzumab - administration & dosage | Xenograft Model Antitumor Assays | Maytansine - administration & dosage | Animals | Uterine Neoplasms - drug therapy | Cell Line, Tumor | Carcinosarcoma - drug therapy | Carcinosarcoma - genetics | Cell Proliferation - drug effects | Mice | Trastuzumab - immunology | Maytansine - immunology | Uterine Neoplasms - immunology | Ovarian Neoplasms - immunology | Biotechnology | Animal models | Toxicity | Tumor cells | Effector cells | Cytotoxicity | Gene expression | ErbB-2 protein | Anticancer properties | Gene amplification | Chemotherapy | Uterus | Experimental design | Cell lines | Xenografts | Antitumor activity | Biocompatibility | In vivo methods and tests | Viability | Trastuzumab | Cancer | SYD985 | T-DM1 | HER2 | Uterine Carcinosarcoma | Ovarian Carcinosarcoma
Journal Article
Cancer Letters, ISSN 0304-3835, 2017, Volume 403, pp. 159 - 164
Abstract Monoallelic germline mutations in one of the DNA mismatch repair (MMR) genes cause Lynch syndrome, with a high lifetime risks of colorectal and... 
Hematology, Oncology and Palliative Medicine | Neoantigens | Prevention | Constitutional mismatch repair deficiency syndrome | CMMRD | Cancer immunotherapy | IMMUNE-RESPONSE | LYNCH-SYNDROME | MICROSATELLITE | DENDRITIC CELL VACCINATION | PD-1 BLOCKADE | EUROPEAN CONSORTIUM CARE | HEREDITARY | ONCOLOGY | COLORECTAL-CANCER | MSH6 MUTATIONS | NIVOLUMAB | Immunotherapy - methods | Neoplastic Syndromes, Hereditary - immunology | Colorectal Neoplasms - genetics | Humans | DNA Repair Enzymes - genetics | DNA Mismatch Repair - genetics | Neoplastic Syndromes, Hereditary - mortality | Cancer Vaccines - therapeutic use | Colorectal Neoplasms - therapy | Brain Neoplasms - immunology | Neoplastic Syndromes, Hereditary - genetics | Brain Neoplasms - mortality | Colorectal Neoplasms - mortality | Antibodies - therapeutic use | Antigens, Neoplasm - genetics | Genetic Predisposition to Disease | Antigens, Neoplasm - immunology | Brain Neoplasms - genetics | Cancer Vaccines - adverse effects | Antibodies - adverse effects | DNA Mismatch Repair - immunology | Immunotherapy - adverse effects | Immunotherapy - mortality | Phenotype | Animals | Colorectal Neoplasms - immunology | Brain Neoplasms - therapy | Neoplastic Syndromes, Hereditary - therapy | Mutation | DNA Repair Enzymes - immunology | Care and treatment | Immune response | Endometrial cancer | Brain tumors | Vaccination | Mortality | Colorectal cancer | Development and progression | T cells | Gene mutations | Gastrointestinal diseases | Tumor antigens | Drug therapy | Cancer | Brain | Brain cancer | Genes | Medical services | Vaccines | Cancer therapies | DNA repair | Risk factors | Intestine | Immunotherapy | Mismatch repair | Children | Repair | Age | Endometrium | Deoxyribonucleic acid--DNA | Immune system | Hematology | Health risks | Patients | Disease prevention | Inhibitors | Immune checkpoint | Health risk assessment | Tumors
Journal Article